Cotellic (cobimetinib) vs Libtayo (cemiplimab)
Cotellic (cobimetinib) vs Libtayo (cemiplimab)
Cotellic (cobimetinib) is a MEK inhibitor used in combination with vemurafenib, a BRAF inhibitor, for the treatment of patients with advanced melanoma that has a specific genetic mutation known as BRAF V600E or V600K. Libtayo (cemiplimab) is a PD-1 blocking antibody used as a monotherapy for patients with advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC) that are metastatic or cannot be cured by surgery or radiation. The choice between Cotellic and Libtayo would depend on the type of cancer, its genetic makeup, and the overall health and treatment goals of the patient, as these medications are not directly interchangeable and target different pathways in cancer treatment.
Difference between Cotellic and Libtayo
| Metric | Cotellic (cobimetinib) | Libtayo (cemiplimab) |
|---|---|---|
| Generic name | cobimetinib | cemiplimab |
| Indications | Used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation | Used for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation |
| Mechanism of action | MEK inhibitor, which works by inhibiting mitogen-activated protein kinase enzymes MEK1 and MEK2 | PD-1 (programmed death receptor-1) blocking antibody |
| Brand names | Cotellic | Libtayo |
| Administrative route | Oral | Intravenous |
| Side effects | Diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting | Fatigue, rash, musculoskeletal pain, diarrhea, and pruritus |
| Contraindications | None known beyond hypersensitivity to cobimetinib or any of its excipients | None known beyond hypersensitivity to cemiplimab or any of its excipients |
| Drug class | Antineoplastic agent, MEK inhibitor | Antineoplastic agent, immune checkpoint inhibitor |
| Manufacturer | Genentech, Inc. | Regeneron Pharmaceuticals, Inc. |
Efficacy
Efficacy of Cotellic (Cobimetinib) in Skin Cancer Treatment
Cotellic (cobimetinib) is a medication that has been approved for use in combination with another drug called Zelboraf (vemurafenib) for the treatment of a specific type of skin cancer known as melanoma. It is specifically indicated for patients with melanoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and whose tumors express a gene mutation called BRAF V600E or V600K, as detected by an FDA-approved test. Cobimetinib is a type of drug known as a MEK inhibitor, which works by interfering with the MEK proteins involved in the growth and spread of cancer cells.
Clinical trials have demonstrated that the combination of cobimetinib and vemurafenib can significantly improve progression-free survival compared to vemurafenib alone in patients with advanced melanoma with the BRAF V600 mutation. This combination has been shown to shrink tumors and prolong the time before the cancer worsens. However, it is important to note that while the combination therapy can be effective, it is not a cure for melanoma and the response to treatment can vary among individuals.
Efficacy of Libtayo (Cemiplimab) in Skin Cancer Treatment
Libtayo (cemiplimab) is a relatively newer medication approved by the FDA for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. CSCC is the second most common form of skin cancer and can be aggressive and difficult to treat in advanced stages. Cemiplimab is a type of immunotherapy drug known as a PD-1 inhibitor, which works by enhancing the body's immune response against cancer cells.
In clinical studies, Libtayo has shown significant efficacy in treating advanced CSCC, with a considerable percentage of patients experiencing tumor shrinkage. The treatment has also been associated with durable responses, meaning that the effects of the therapy are sustained over a period of time. As a monotherapy, cemiplimab has provided a new treatment option for patients with advanced CSCC, offering hope for improved outcomes in a disease that previously had limited effective systemic therapies.
Regulatory Agency Approvals
Cotellic
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Therapeutic Goods Administration (TGA), Australia
Libtayo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
Access Cotellic or Libtayo today
If Cotellic or Libtayo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us